SCHEMBL7162150

SCHEMBL7162150

Nc1nc(N)c(-c2ccccc2)c(N)n1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 7/20 0.66
HEXA P06865 1/20 0.66
HEXB P07686 1/20 0.66
ADORA2A P29274 2/20 0.56
ADORA1 P30542 2/20 0.56
POLB P06746 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ADORA2B P29275 1/20 0.56
CSNK1A1 P48729 1/20 0.54
CLK4 Q9HAZ1 1/20 0.54
KDM4E B2RXH2 2/20 0.53
MAPK1 P28482 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
MAPT P10636 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
DCPS Q96C86 1/20 0.52
PIK3CG P48736 1/20 0.52
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2D6 P10635 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473930 0.87 DHFR (0.58) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL3500167 0.85 DHFR (0.61) DHFRHEXAHEXBADORA2AKDM4E
Hydrochloric Acid SCHEMBL15487768 0.85 DHFR (0.56) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL1031028 0.85 DHFR (0.56) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL3498787 0.80 HEXA (1.00) DHFRHEXAHEXBTDP1CYP1A2
SCHEMBL28594009 0.80 DHFR (0.56) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL29115860 0.80 MAPK1 (0.53) DHFRHEXAHEXBADORA2AADORA1
SCHEMBL5064901 0.79 DHFR (0.50) DHFRHEXAHEXBADORA2AADORA1
Biphenyl SCHEMBL183386 0.78 ADORA2A (0.75) DHFRADORA2AADORA1POLBADORA3
SCHEMBL3502224 0.78 DHFR (0.78) DHFRHEXAHEXBTDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105348203-B Inhibit the composition and method of JAK approach 里格尔药品股份有限公司 2018-09-18 CN disclosed
EP-1363638-A2 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS Synaptic Pharmaceutical Corporation (US) 2003-11-26 EP disclosed
WO-2002060392-A2 USE OF GAL3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2002-08-08 WO disclosed